Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Imcyse

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

Details:

Positive interim biomarker Phase 2 IMPACT Type 1 Diabetes Study data support specific immune signature induced by Imotope (IMCY-0098) and effect on potentially pathogenic T cells.

Lead Product(s): IMCY-0098

Therapeutic Area: Endocrinology Product Name: Imotope

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY